METiS Therapeutics Secures USD 100 Million in Series C Financing to Advance AI Drug Delivery
METiS Therapeutics, a biopharmaceutical company based in Cambridge, Massachusetts, has secured USD 100 million in...
METiS Therapeutics
Evopoint Biosciences Licenses SOS1 Inhibitor to METiS Therapeutics
China-based Evopoint Biosciences has announced a global licensing agreement with US firm METiS Therapeutics Inc.,...
METiS Therapeutics In-Licenses Voronoi’s Pan-RAF Inhibitor Program
Cambridge, Massachusetts-based METiS Therapeutics has unveiled its first in-license deal, signing with South Korea’s Voronoi...